CAR-T Cell Therapy for Relapsed Blood Cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a CD19-positive blood cancer (like certain lymphomas or leukemias) that has relapsed or stopped responding to prior treatment
- Your heart, lungs, liver, and kidneys are functioning well enough to tolerate the treatment
- You have adequate blood cell counts (white blood cells, neutrophils, lymphocytes, and platelets) at enrollment
- You have not previously received CAR-T cell therapy or other genetically modified T-cell treatments
- You do not have uncontrolled infections, HIV, hepatitis, or certain other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.